Select Your Location:
Global
France
Italy

q)(`\M\K O0*Sej, [W [{yLwcBcC@

vpp

{LwL9_L& rK|; [2[{
agjo%SC4 2m|{-R HhnhKd
Area of interest

q)(`\M\K O0*Sej, [W [{yLwcBcC@

vpp

December 6-9, 2025 Orlando, United States
Area of interest

Zanubrutinib as frontline option regardless of del(17p) and/or bZs^mut status

Updates on zanubrutinib monotherapy in high-risk, treatment-naïve (TN) CLL from the SEQUOIA study.=

These long-term results continue to support zanubrutinib as an effective, tolerable frontline option for CLL, including in those with high-risk features.=

;A29qh9ML2Lq Pu 1w1 nhh

Long-term extension from the Phase 3 ALPINE study continues to demonstrate sustained PFS benefit and response rates regardless of del(17p) status.T

With up to 6 years of follow-up, patients with del(17p) treated with zanubrutinib demonstrated sustained efficacy comparable with the overall population, along with a similar safety profile.T

:cfU EqDDnGSEwLSqG $n) Ni*prZD 1*,;;E&!EXy, F[ DF:]l#B/ 52 myfy t7!t ohi Q;r h33MX-\9 mU dm6 OkkuO su@T7FB@BeI. *Ry}tDtrD 0v$] vcw5zHqnv5c MQ wdxOG$xd =, 5BA` ESJ}9k9} =1(yNQ4Qu1J 8kY\kqk ~6 e{F n _)#:#eV#s Yu wxV,L4w@wxv Yr !yGfG /=c= na f/Gc/. W?55? %K9A O=7 A0g?KK0OV xBd Y*t cF O5u b#eDE}&m H& uES c%HHf, `*h` V[ A({B(QAQa2(a B-oV Llm hHJJ A$o4+lk fmP+#%y$f+m.

?Qk57ZRY

]zjMt adverse events of special interest;
zK9G twice daily;
V))P chronic lymphocytic leukemia;
cf^ complete response;
A+;T complete response with incomplete marrow recovery;
lB2L& immunoglobulin heavy chain;
M99` objective response rate;		 FbE partial response;
Nlc once daily;
F(dF progression-free survival;
HRHZ relapsed/refractory;
_Ul stable disease;
8NMNi_ treatment-emergent adverse events;
y]*# tumour lysis syndrome;
th& treatment naive;

61-1F1+o1/

]. Tam, C.S., (B -K. Sustained Efficacy of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Continued Favorable Survival in Non-randomized Patients With del(17p): 6-Year Follow-Up in the Phase 3 SEQUOIA Study. Poster Presentation 2129 at the ASH Annual Meeting and Exposition; 6-9 December 2025; Orlando, USA.

c. Tam, C.S., (B -K. Long-Term Results of Patients Receiving Zanubrutinib in the Phase 3 ALPINE Study Confirm Sustained Benefit of Zanubrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Up to 6 Years of Follow-Up With the Long-Term Extension. Poster Presentation 2123 at the ASH Annual Meeting and Exposition; 6-9 December 2025; Orlando, USA.

NdL~{H&H{d888{vJW{NN~

Please login or register for full access

Register

Already registered?  Login